How can a ZIIHERA treatment plan benefit you?

Start with a chance at a longer life

Many people who received ZIIHERA + tislelizumab (immunotherapy) + chemotherapy lived more than two years after starting treatment, the longest results reported in a clinical trial for your cancer.

You may hear your care team refer to this as “OS,” or .

Clock icon

Living longer than what was seen before

Keeping cancer from
getting worse

The study also looked at how long treatment could keep cancer from growing or spreading.

Many people who received a ZIIHERA treatment plan lived more than 1 year without their cancer getting worse, the longest results reported in a clinical trial for your cancer.

You may hear your care team refer to this as “PFS,” or .

Calendar icon

More time without cancer growing or spreading

Explore detailed results for each ZIIHERA treatment plan below:

Backed by the largest clinical trial for your type of cancer

The clinical trial for ZIIHERA included over 900 adults with previously untreated HER2-positive advanced GEA:

People icon
  • 302 people received ZIIHERA with tislelizumab () and chemotherapy
  • 304 people received ZIIHERA with chemotherapy alone
  • The results for both ZIIHERA treatment plans were compared to 308 people who received trastuzumab + chemotherapy. This was the commonly used treatment plan for this type of cancer before ZIIHERA was available

Find information you should know when taking ZIIHERA.

Side effects

What is ZIIHERA?

ZIIHERA (zanidatamab-hrii) 50 mg/mL is a prescription medicine used to treat adults with gastroesophageal cancer (GEA) including gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) cancer. ZIIHERA is used in combination with fluoropyrimidine- and platinum-containing chemotherapy with or without tislelizumab-jsgr as the first treatment when your GEA:

  • cannot be removed by surgery or has spread to other parts of your body (metastatic); and
  • your tumor tests positive for human epidermal growth factor receptor 2 (HER2 IHC 3+ or IHC 2+/ISH+).

Your healthcare provider will perform a test to make sure ZIIHERA is right for you.

It is not known if ZIIHERA is safe and effective in children.

IMPORTANT SAFETY INFORMATION

ZIIHERA can cause serious side effects, including:

  • Diarrhea. Diarrhea during treatment with ZIIHERA can be severe, life threatening, and can lead to death. Diarrhea may cause loss of fluids and body salts (electrolytes). To help prevent or reduce diarrhea during treatment with ZIIHERA, your healthcare provider:
    • will tell you to drink more fluids.
    • start you on an antidiarrheal medicine such as loperamide or other treatment, as needed.
    • may temporarily stop, reduce your dose or permanently stop treatment with ZIIHERA, or other medicines you take.

If you get new or worsening diarrhea, tell your healthcare provider right away and take antidiarrheal medicine as prescribed. Follow all of your healthcare providers instructions to help with your diarrhea.

  • Harm to your unborn baby. Taking ZIIHERA during pregnancy or within 4 months before pregnancy can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ZIIHERA.

Females who are able to become pregnant:

  • Your healthcare provider should do a pregnancy test before you start treatment with ZIIHERA.
  • Use effective birth control (contraception) during treatment with ZIIHERA and for 4 months after the last dose.

  • Heart problems that may affect how well your heart pumps blood. Your healthcare provider will check your heart function before and during treatment with ZIIHERA. Tell your healthcare provider right away if you get any of the following signs and symptoms of a heart problem:

    • new or worsening shortness of breath
    • feeling more tired than usual
    • swelling of your ankles or feet
    • loss of consciousness
    • irregular heartbeat
    • sudden weight gain
    • dizziness or feeling light-headed

  • Infusion-related reactions. Your healthcare provider will check for side effects during your infusions. Tell your healthcare provider right away if you get any of the following symptoms during or after your infusions of ZIIHERA:

    • shortness of breath or trouble breathing
    • fever
    • chills
    • rash
    • flushing
    • nausea or vomiting
    • dizziness or feeling light-headed
    • chest discomfort

Before receiving ZIIHERA, tell your healthcare provider about all of your medical conditions, including if you:

  • have or have had any heart problems.
  • are breastfeeding or plan to breastfeed. It is not known if ZIIHERA passes into your breastmilk. Talk to your healthcare provider about the best way to feed your baby if you receive treatment with ZIIHERA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Other common side effects when ZIIHERA is given in combination with chemotherapy and tislelizumab-jsgr include:

  • diarrhea
  • nausea
  • decreased appetite
  • low levels of blood potassium
  • vomiting
  • feeling tired
  • numbness, pain, tingling, or burning in your hands or feet
  • rash
  • infusion-related reactions

Other common side effects when ZIIHERA is given in combination with chemotherapy include:

  • diarrhea
  • nausea
  • vomiting
  • numbness, pain, tingling, or burning in your hands or feet
  • decreased appetite
  • feeling tired
  • low levels of blood potassium
  • infusion-related reactions
  • rash

These are not all the possible side effects of ZIIHERA. Call your doctor for medical advice about side effects.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Please see the full Prescribing Information, including BOXED WARNINGS and Medication Guide, and discuss with your doctor.